Vimta Labs Limited has informed the Exchange about Investor Presentation
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vimta Labs reported Q4 FY26 total income of Rs 1,120 Mn (up 15.2% YoY) with EBITDA at Rs 421 Mn (37.6% margin) and PAT of Rs 211 Mn (18.9% margin). For full year FY26, total income stood at Rs 4,163 Mn (up 16.6% YoY), EBITDA at Rs 1,489 Mn (35.8% margin), and PAT at Rs 775 Mn (18.6% margin), with EPS of Rs 17.4. The company operates in contract research and testing (CRTO) across pharma, food, electronics, and environment testing segments. It holds #1 positions in India in pharma analytical and food testing. Revenue CAGR over FY20–FY26 was 14.6%, while EBITDA CAGR was 28.6%. Cash position is strong at Rs 650.6 Mn against a low debt of Rs 33.3 Mn.
Strong profitability and cash position support financial stability; however, EBITDA margin in FY26 (35.8%) contracted slightly versus FY25 (36.2%), suggesting margin pressure to monitor. The company's diverse CRTO services and leadership positions in pharma and food testing position it well for continued growth.